Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome.
- 1 July 1988
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 6 (7) , 1125-1133
- https://doi.org/10.1200/jco.1988.6.7.1125
Abstract
Clinical and histopathologic data from 87 patients with primary non-Hodgkin's lymphoma of the gastrointestinal (GI) tract diagnosed between 1974 and 1984 were reviewed. B-cell lymphomas of intermediate- or high-grade histology constituted 78% of lesions. Stage of disease varied with histologic grade, with a preponderance of advanced disease (stages IIIE and IV) in patients with low-grade lymphoma (15 of 21) (71%), compared with higher grade lesions (38%, P = .01). Among patients with nonlocalized (stages IIE through IV) lymphoma of intermediate- or high-grade histology, surgical resection of the primary focus afforded a higher rate of complete remission (CR) (70% v 50%) and sustained CR (61% v 21%, P = .04) after cytotoxic therapy compared with the nonresected cohort. The median survival in the resected group was 51 months + compared with 13 months in the nonresected patients (P = .012). Differences in outcome were attributable to a high risk of treatment-related complications (perforation and/or hemorrhage) (43% v 0%, P = .001) and local relapse (29% v 4%, P = .05) in nonresected individuals. Life-threatening local complications were not observed in patients with low-grade lymphoma managed solely with medical therapy. Histologic findings from surgically staged patients identified presence of extravisceral disease and intermediate- or high-grade tumor histology as features predictive of transmural invasion, enabling potential identification of patients who might be optimally managed by resection of the primary GI focus before initiation of cytotoxic therapy.This publication has 20 references indexed in Scilit:
- Cyclophosphamide, Vincristine, Methotrexate with Leucovorin Rescue, and Cytarabine (COMLA) Combination Sequential Chemotherapy for Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1980
- Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experienceCancer, 1980
- Malignant lymphomas of follicular center cell origin in man.III. Prognostic FeaturesCancer, 1979
- Lymphomas of the gastrointestinal tract.A study of 117 cases presenting with gastrointestinal diseaseCancer, 1978
- Diffuse histiocytic lymphoma involving the gastrointestinal tractCancer, 1978
- Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapyThe American Journal of Medicine, 1977
- Treatment Results of 54 American Patients with Burkitt's Lymphoma Are Similar to the African ExperienceNew England Journal of Medicine, 1977
- Factors in the prognosis of gastric lymphomaCancer, 1977
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976
- Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1976